Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children
Aim To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children. Methods All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between No...
Gespeichert in:
| Veröffentlicht in: | Archives of disease in childhood 2010-06, Vol.95 (6), p.478-481 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 481 |
|---|---|
| container_issue | 6 |
| container_start_page | 478 |
| container_title | Archives of disease in childhood |
| container_volume | 95 |
| creator | Rudin, Christoph Wolbers, Marcel Nadal, David Rickenbach, Martin Bucher, Heiner C |
| description | Aim To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children. Methods All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included. Results 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45–3.17; PI-naive, n=17) and 2.53 (3.68–1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203–593; PI-naive) and 177 (21–331; PI-experienced) cells/µl. These effects remained stablethroughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children. Conclusion Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children. |
| doi_str_mv | 10.1136/adc.2009.169375 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1828792828</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A233316488</galeid><sourcerecordid>A233316488</sourcerecordid><originalsourceid>FETCH-LOGICAL-b506t-a20c7cf2e7ab34ac84d530927c10431add494325c2c2a417544f1170acddfd163</originalsourceid><addsrcrecordid>eNqFkU1vEzEQhi0EomnhzA2thLggbeKv3fUe24h-SIFeSq-WY4-Dw8YOtlO1_x4vG9ojF9ujeTzzSC9CHwieE8LahTJ6TjHu56TtWde8QjPCW1FTzPlrNMMYs7oXQpyg05S2GBMqBHuLTihuMGk4naGwCn5TZ4i7KikL-alS3lRgLejsHsBDSlWw1RD2zqsHFxfR5fD3VTlf2Owi5BhKrYYaHvcQHXgNprq-ua9J7fw4qJT6pxtMBP8OvbFqSPD-eJ-hH5df75bX9er26mZ5vqrXDW5zrSjWnbYUOrVmXGnBTcNwTztNMGdEGcN7zmijqaaKk67h3BLSYaWNsYa07Ax9mubuY_h9gJTlNhyiLyslEVR0PS1noeqJ2qgBpPM6-AyPWYdhgA3IYrS8leeUMUZaLkZ-MfE6hpQiWLmPbqfikyRYjoHIEogcA5FTIOXHx6PHYb0D88z_S6AAn4-ASloNNiqvXXrhiqXoaP-i6lJRfO6r-Eu2Xdkkv98v5QX9drlq7pZynPtl4te77X8t_wC0i683</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1828792828</pqid></control><display><type>article</type><title>Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Rudin, Christoph ; Wolbers, Marcel ; Nadal, David ; Rickenbach, Martin ; Bucher, Heiner C</creator><creatorcontrib>Rudin, Christoph ; Wolbers, Marcel ; Nadal, David ; Rickenbach, Martin ; Bucher, Heiner C ; Swiss Mother and Child HIV Cohort Study (MoCHiV) ; Pediatric Infectious Disease Group of Switzerland (PIGS) ; the Pediatric Infectious Disease Group of Switzerland (PIGS) and the Swiss Mother and Child HIV Cohort Study (MoCHiV)</creatorcontrib><description>Aim To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children. Methods All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included. Results 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45–3.17; PI-naive, n=17) and 2.53 (3.68–1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203–593; PI-naive) and 177 (21–331; PI-experienced) cells/µl. These effects remained stablethroughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children. Conclusion Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children.</description><identifier>ISSN: 0003-9888</identifier><identifier>EISSN: 1468-2044</identifier><identifier>DOI: 10.1136/adc.2009.169375</identifier><identifier>PMID: 20501542</identifier><identifier>CODEN: ADCHAK</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</publisher><subject>Adolescent ; Antiretroviral agents ; Biological and medical sciences ; CD4 Lymphocyte Count ; Child ; Child, Preschool ; Children ; Data Analysis ; Diseases ; Drug therapy ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; General aspects ; Health aspects ; HIV infection ; HIV infections ; HIV Infections - drug therapy ; HIV Infections - immunology ; HIV Infections - virology ; HIV Protease Inhibitors - adverse effects ; HIV Protease Inhibitors - therapeutic use ; HIV-1 - isolation & purification ; Human viral diseases ; Humans ; Immunology ; Infectious diseases ; Lopinavir ; Male ; Medical sciences ; Miscellaneous ; Observation ; Patients ; Pediatric diseases ; Prevention and actions ; Prospective Studies ; Proteinase inhibitors ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Pyrimidinones - adverse effects ; Pyrimidinones - therapeutic use ; Ritonavir ; Ritonavir - adverse effects ; Ritonavir - therapeutic use ; Treatment Outcome ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral Load</subject><ispartof>Archives of disease in childhood, 2010-06, Vol.95 (6), p.478-481</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2015 INIST-CNRS</rights><rights>Copyright: 2010 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b506t-a20c7cf2e7ab34ac84d530927c10431add494325c2c2a417544f1170acddfd163</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://adc.bmj.com/content/95/6/478.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://adc.bmj.com/content/95/6/478.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,315,782,786,3200,23580,27933,27934,77610,77641</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22838729$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20501542$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rudin, Christoph</creatorcontrib><creatorcontrib>Wolbers, Marcel</creatorcontrib><creatorcontrib>Nadal, David</creatorcontrib><creatorcontrib>Rickenbach, Martin</creatorcontrib><creatorcontrib>Bucher, Heiner C</creatorcontrib><creatorcontrib>Swiss Mother and Child HIV Cohort Study (MoCHiV)</creatorcontrib><creatorcontrib>Pediatric Infectious Disease Group of Switzerland (PIGS)</creatorcontrib><creatorcontrib>the Pediatric Infectious Disease Group of Switzerland (PIGS) and the Swiss Mother and Child HIV Cohort Study (MoCHiV)</creatorcontrib><title>Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children</title><title>Archives of disease in childhood</title><addtitle>Arch Dis Child</addtitle><description>Aim To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children. Methods All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included. Results 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45–3.17; PI-naive, n=17) and 2.53 (3.68–1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203–593; PI-naive) and 177 (21–331; PI-experienced) cells/µl. These effects remained stablethroughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children. Conclusion Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children.</description><subject>Adolescent</subject><subject>Antiretroviral agents</subject><subject>Biological and medical sciences</subject><subject>CD4 Lymphocyte Count</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Data Analysis</subject><subject>Diseases</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>General aspects</subject><subject>Health aspects</subject><subject>HIV infection</subject><subject>HIV infections</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - virology</subject><subject>HIV Protease Inhibitors - adverse effects</subject><subject>HIV Protease Inhibitors - therapeutic use</subject><subject>HIV-1 - isolation & purification</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunology</subject><subject>Infectious diseases</subject><subject>Lopinavir</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Observation</subject><subject>Patients</subject><subject>Pediatric diseases</subject><subject>Prevention and actions</subject><subject>Prospective Studies</subject><subject>Proteinase inhibitors</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Pyrimidinones - adverse effects</subject><subject>Pyrimidinones - therapeutic use</subject><subject>Ritonavir</subject><subject>Ritonavir - adverse effects</subject><subject>Ritonavir - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral Load</subject><issn>0003-9888</issn><issn>1468-2044</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkU1vEzEQhi0EomnhzA2thLggbeKv3fUe24h-SIFeSq-WY4-Dw8YOtlO1_x4vG9ojF9ujeTzzSC9CHwieE8LahTJ6TjHu56TtWde8QjPCW1FTzPlrNMMYs7oXQpyg05S2GBMqBHuLTihuMGk4naGwCn5TZ4i7KikL-alS3lRgLejsHsBDSlWw1RD2zqsHFxfR5fD3VTlf2Owi5BhKrYYaHvcQHXgNprq-ua9J7fw4qJT6pxtMBP8OvbFqSPD-eJ-hH5df75bX9er26mZ5vqrXDW5zrSjWnbYUOrVmXGnBTcNwTztNMGdEGcN7zmijqaaKk67h3BLSYaWNsYa07Ax9mubuY_h9gJTlNhyiLyslEVR0PS1noeqJ2qgBpPM6-AyPWYdhgA3IYrS8leeUMUZaLkZ-MfE6hpQiWLmPbqfikyRYjoHIEogcA5FTIOXHx6PHYb0D88z_S6AAn4-ASloNNiqvXXrhiqXoaP-i6lJRfO6r-Eu2Xdkkv98v5QX9drlq7pZynPtl4te77X8t_wC0i683</recordid><startdate>20100601</startdate><enddate>20100601</enddate><creator>Rudin, Christoph</creator><creator>Wolbers, Marcel</creator><creator>Nadal, David</creator><creator>Rickenbach, Martin</creator><creator>Bucher, Heiner C</creator><general>BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</general><general>BMJ Publishing Group</general><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88B</scope><scope>88E</scope><scope>88I</scope><scope>8A4</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>CJNVE</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0P</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEDU</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20100601</creationdate><title>Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children</title><author>Rudin, Christoph ; Wolbers, Marcel ; Nadal, David ; Rickenbach, Martin ; Bucher, Heiner C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b506t-a20c7cf2e7ab34ac84d530927c10431add494325c2c2a417544f1170acddfd163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adolescent</topic><topic>Antiretroviral agents</topic><topic>Biological and medical sciences</topic><topic>CD4 Lymphocyte Count</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Data Analysis</topic><topic>Diseases</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>General aspects</topic><topic>Health aspects</topic><topic>HIV infection</topic><topic>HIV infections</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - virology</topic><topic>HIV Protease Inhibitors - adverse effects</topic><topic>HIV Protease Inhibitors - therapeutic use</topic><topic>HIV-1 - isolation & purification</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunology</topic><topic>Infectious diseases</topic><topic>Lopinavir</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Observation</topic><topic>Patients</topic><topic>Pediatric diseases</topic><topic>Prevention and actions</topic><topic>Prospective Studies</topic><topic>Proteinase inhibitors</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Pyrimidinones - adverse effects</topic><topic>Pyrimidinones - therapeutic use</topic><topic>Ritonavir</topic><topic>Ritonavir - adverse effects</topic><topic>Ritonavir - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rudin, Christoph</creatorcontrib><creatorcontrib>Wolbers, Marcel</creatorcontrib><creatorcontrib>Nadal, David</creatorcontrib><creatorcontrib>Rickenbach, Martin</creatorcontrib><creatorcontrib>Bucher, Heiner C</creatorcontrib><creatorcontrib>Swiss Mother and Child HIV Cohort Study (MoCHiV)</creatorcontrib><creatorcontrib>Pediatric Infectious Disease Group of Switzerland (PIGS)</creatorcontrib><creatorcontrib>the Pediatric Infectious Disease Group of Switzerland (PIGS) and the Swiss Mother and Child HIV Cohort Study (MoCHiV)</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Education Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Education Periodicals</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Education Collection</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Education Database</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Education</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Archives of disease in childhood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rudin, Christoph</au><au>Wolbers, Marcel</au><au>Nadal, David</au><au>Rickenbach, Martin</au><au>Bucher, Heiner C</au><aucorp>Swiss Mother and Child HIV Cohort Study (MoCHiV)</aucorp><aucorp>Pediatric Infectious Disease Group of Switzerland (PIGS)</aucorp><aucorp>the Pediatric Infectious Disease Group of Switzerland (PIGS) and the Swiss Mother and Child HIV Cohort Study (MoCHiV)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children</atitle><jtitle>Archives of disease in childhood</jtitle><addtitle>Arch Dis Child</addtitle><date>2010-06-01</date><risdate>2010</risdate><volume>95</volume><issue>6</issue><spage>478</spage><epage>481</epage><pages>478-481</pages><issn>0003-9888</issn><eissn>1468-2044</eissn><coden>ADCHAK</coden><abstract>Aim To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children. Methods All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included. Results 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45–3.17; PI-naive, n=17) and 2.53 (3.68–1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203–593; PI-naive) and 177 (21–331; PI-experienced) cells/µl. These effects remained stablethroughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children. Conclusion Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</pub><pmid>20501542</pmid><doi>10.1136/adc.2009.169375</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-9888 |
| ispartof | Archives of disease in childhood, 2010-06, Vol.95 (6), p.478-481 |
| issn | 0003-9888 1468-2044 |
| language | eng |
| recordid | cdi_proquest_journals_1828792828 |
| source | MEDLINE; BMJ Journals - NESLi2 |
| subjects | Adolescent Antiretroviral agents Biological and medical sciences CD4 Lymphocyte Count Child Child, Preschool Children Data Analysis Diseases Drug therapy Drug Therapy, Combination Female Follow-Up Studies General aspects Health aspects HIV infection HIV infections HIV Infections - drug therapy HIV Infections - immunology HIV Infections - virology HIV Protease Inhibitors - adverse effects HIV Protease Inhibitors - therapeutic use HIV-1 - isolation & purification Human viral diseases Humans Immunology Infectious diseases Lopinavir Male Medical sciences Miscellaneous Observation Patients Pediatric diseases Prevention and actions Prospective Studies Proteinase inhibitors Public health. Hygiene Public health. Hygiene-occupational medicine Pyrimidinones - adverse effects Pyrimidinones - therapeutic use Ritonavir Ritonavir - adverse effects Ritonavir - therapeutic use Treatment Outcome Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Load |
| title | Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T09%3A46%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20safety%20and%20effectiveness%20of%20lopinavir/ritonavir%20in%20antiretroviral-experienced%20HIV-1-infected%20children&rft.jtitle=Archives%20of%20disease%20in%20childhood&rft.au=Rudin,%20Christoph&rft.aucorp=Swiss%20Mother%20and%20Child%20HIV%20Cohort%20Study%20(MoCHiV)&rft.date=2010-06-01&rft.volume=95&rft.issue=6&rft.spage=478&rft.epage=481&rft.pages=478-481&rft.issn=0003-9888&rft.eissn=1468-2044&rft.coden=ADCHAK&rft_id=info:doi/10.1136/adc.2009.169375&rft_dat=%3Cgale_proqu%3EA233316488%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1828792828&rft_id=info:pmid/20501542&rft_galeid=A233316488&rfr_iscdi=true |